For people now taking medicines from a company which was not pursuing CGMP, FDA typically advises these consumers never to interrupt their drug therapy, which could have significant implications for their wellbeing. Consumers should seek guidance from their wellness treatment specialists just before halting or switching remedies. Regulatory actions